Voyager reports Q3 2026 results, cash runway into Q2 2028
The company said VY7523 tau PET data remain on track for Q4 2026 and VY1706 dosing should begin within months, pending enrollment.
SEC filing
7 stories
The company said VY7523 tau PET data remain on track for Q4 2026 and VY1706 dosing should begin within months, pending enrollment.
SEC filing
Neurocrine reported 41% revenue growth for the third quarter of 2026 and lifted full-year INGREZZA guidance while advancing new obesity and Alzheimer's programs.
SEC filing
The Board made the change effective September 28, 2026, after Keswani's departure was agreed on September 25.
SEC filing